Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2009

Eureka Genomics’ First Sequencing Center to Use Illumina Technology

  • Eureka Genomics is launching its first Eureka Genomics Center in North America and will use the Illumina Genome Analyzer. The company plans to open 15 more centers around the world.

    The next three centers are scheduled to open in Southeast Asia, Central America, and Europe, all within 12 months. “We are very excited to finally provide our customers with a one-stop shop from DNA extraction, sample preparation, next-generation sequencing, post sequencing, and advanced bioinformatics analysis," says Michael Tippie, vp of business development for Eureka Genomics.

    For the first four months of 2009, Eureka Genomics reports receiving over $500,000 in orders for its next-generation sequencing and bioinformatics services. The firm forecasts over $3 million in sales over the next year.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »